1.Facile synthesis of TiO2-RGO composite with enhanced performance for the photocatalytic mineralization of organic pollutants.
Nainani RK1, Thakur P1. Water Sci Technol. 2016;73(8):1927-36. doi: 10.2166/wst.2016.039.
Current research reports the synthesis of reduced graphene oxide (RGO)-TiO2 nanocomposite by in-situ redox method and graphene oxide by modified hummers method. The ratio of RGO and TiO2 in the composite was optimized to show best photocatalytic activity for the degradation of targeted pollutants. Optimized (1:10) RGO-TiO2 nanocomposite was characterized by various techniques viz. X-ray diffraction (XRD), transmission electron microscopy (TEM), thermogravimetric analysis (TGA), Brunauer-Emmett-Teller surface area (BET), Raman and diffuse reflectance spectroscopy (DRS) technique confirming successful formation of nanocomposite. XRD results confirm the presence of anatase phase in RGO-TiO2. Uniform dispersion of TiO2 nanoparticles on RGO could be seen from TEM images. The obtained results of (1:10) RGO-TiO2 showed five-fold and two-fold enhancement for the visible light and UV light, respectively, for the photocatalytic mineralization of methylene blue dye as compared to commercial Aeroxide P25 TiO2.
2.Identification of lipid-phosphatidylserine (PS) as the target of unbiasedly selected cancer specific peptide-peptoid hybrid PPS1.
Desai TJ1, Toombs JE2, Minna JD2,3,4,5, Brekken RA2,3,4,6, Udugamasooriya DG1,7. Oncotarget. 2016 Apr 22. doi: 10.18632/oncotarget.8929. [Epub ahead of print]
Phosphatidylserine (PS) is an anionic phospholipid maintained on the inner-leaflet of the cell membrane and is externalized in malignant cells. We previously launched a careful unbiased selection targeting biomolecules (e.g. protein, lipid or carbohydrate) distinct to cancer cells by exploiting HCC4017 lung cancer and HBEC30KT normal epithelial cells derived from the same patient, identifying HCC4017 specific peptide-peptoid hybrid PPS1. In this current study, we identified PS as the target of PPS1. We validated direct PPS1 binding to PS using ELISA-like assays, lipid dot blot and liposome based binding assays. In addition, PPS1 recognized other negatively charged and cancer specific lipids such as phosphatidic acid, phosphatidylinositol and phosphatidylglycerol. PPS1 did not bind to neutral lipids such as phosphatidylethanolamine found in cancer and phosphatidylcholine and sphingomyelin found in normal cells. Further we found that the dimeric version of PPS1 (PPS1D1) displayed strong cytotoxicity towards lung cancer cell lines that externalize PS, but not normal cells.
3.Bicarbonate Values for Healthy Residents Living in Cities Above 1500 Meters of Altitude: A Theoretical Model and Systematic Review.
Ramirez-Sandoval JC1, Castilla-Peón MF2, Gotés-Palazuelos J1, Vázquez-García JC3, Wagner MP4, Merelo-Arias CA2, Vega-Vega O1,5, Rincón-Pedrero R1, Correa-Rotter R1. High Alt Med Biol. 2016 Apr 27. [Epub ahead of print]
Ramirez-Sandoval, Juan C., Maria F. Castilla-Peón, José Gotés-Palazuelos, Juan C. Vázquez-García, Michael P. Wagner, Carlos A. Merelo-Arias, Olynka Vega-Vega, Rodolfo Rincón-Pedrero, and Ricardo Correa-Rotter. Bicarbonate values for healthy residents living in cities above 1500 m of altitude: a theoretical model and systematic review. High Alt Med Biol 00:000-000, 2016-Plasma bicarbonate (HCO3-) concentration is the main value used to assess the metabolic component of the acid-base status. There is limited information regarding plasma HCO3- values adjusted for altitude for people living in cities at high altitude defined as 1500 m (4921 ft) or more above sea level. Our aim was to estimate the plasma HCO3- concentration in residents of cities at these altitudes using a theoretical model and compare these values with HCO3- values found on a systematic review, and with those venous CO2 values obtained in a sample of 633 healthy individuals living at an altitude of 2240 m (7350 ft).
4.Mesothelin's minimal MUC16 binding moiety converts TR3 into a potent cancer therapeutic via hierarchical binding events at the plasma membrane.
Su Y1,2, Tatzel K1, Wang X1, Belt B1, Binder P3, Kuroki L3, Powell MA3,4, Mutch DG3,4, Hawkins WG1,4, Spitzer D1,4. Oncotarget. 2016 Apr 22. doi: 10.18632/oncotarget.8925. [Epub ahead of print]
TRAIL has been extensively explored as a cancer drug based on its tumor-selective activity profile but it is incapable per se of discriminating between death receptors expressed by normal host cells and transformed cancer cells. Furthermore, it is well documented that surface tethering substantially increases its biologic activity. We have previously reported on Meso-TR3, a constitutive TRAIL trimer targeted to the biomarker MUC16 (CA125), in which the entire ectodomain of human mesothelin was genetically fused to the TR3 platform, facilitating attachment to the cancer cells via the MUC16 receptor. Here, we designed a truncation variant, in which the minimal 64 amino acid MUC16 binding domain of mesothelin was incorporated into TR3. It turned out that the dual-domain biologic Meso64-TR3 retained its high MUC16 affinity and bound to the cancer cells quickly, independent of the TR3/death receptor interaction. Furthermore, it was substantially more potent than Meso-TR3 and TR3 in vitro and in a preclinical xenograft model of MUC16-dependent ovarian cancer.